GSK’s Blenrep Wins BCMA Race, Carries Ocular Toxicity Warning
Executive Summary
US FDA-approved belantamab mafodotin is indicated for heavily pre-treated multiple myeloma and has a list price of $23,900 per month. Its REMS could limit initial uptake, but response rates have been encouraging.
You may also be interested in...
Janssen/Legend Plan Phased US Launch For BCMA-Targeting CAR-T Carvykti
Janssen priced the one-time autologous treatment at $465,000, well above the $419,500 list price for Bristol’s first-to-market CAR-T, but expects broad commercial and Medicare coverage.
Multiple Myeloma Bispecifics Vie For Leadership Based On Safety, Combinability
Updates at ASH for bispecifics targeting BCMA, GPRC5D and FcRH5 from Regeneron, Janssen, Pfizer, Roche, AbbVie and Harpoon show monotherapy efficacy, initial combination data and potential safety differentiation.
Free Eye Drops Distribution To Mitigate Drug Side Effects Cleared By HHS OIG
Program relies on a third-party vendor managing a Risk Evaluation and Mitigation Strategy associated with the drug to facilitate delivery of eye drops to patients.